gammaCore is selected for Innovation and Technology Payment program to treat cluster headache through NHS England

elctroCore Inc announced that gammaCore, the company’s non-invasive vagus nerve stimulator (nVNS), has been selected through a highly competitive process for the Innovation and Technology Payment (ITP) Program by NHS England for use in the treatment of cluster headache in adults. Through this program, gammaCore will become a funded option for the 55,000 patients in England who suffer from cluster headache and their providers.

The ITP Program is designed to support the adoption of innovations and technologies in the NHS market through the removal of significant financial barriers for both commissioners and providers. The program provides funding to these MedTech products and promotes a broader set of activities with Academic Health Science Networks (AHSNs) in order to deliver improvements in the quality and efficacy of patient care. gammaCore will be centrally funded by the NHS and the ITP will work to increase the momentum of adoption throughout England. The ITP Program will go into effect for a one-year period beginning in Q2 of this year.